Silexion Therapeutics earnings were -$14.0M for the trailing 12 months ending Jun 30, 2026, with N/A growth year over year. The latest SLXN earnings report on Jun 30, 2026 announced Q2 2026 earnings of -$3.6M, up 29.9% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, SLXN reported annual earnings of -$11.9M, with -27.9% growth.
Silexion Therapeutics Earnings Reports & History FAQ
What were Silexion Therapeutics's earnings last quarter?
On SLXN's earnings call on Aug 18, 2026, Silexion Therapeutics (NASDAQ: SLXN) reported Q2 2026 earnings per share (EPS) of -$5.17, up 88.03% year over year. Total SLXN earnings for the quarter were -$3.55 million. In the same quarter last year, Silexion Therapeutics's earnings per share (EPS) was -$43.19.
Is Silexion Therapeutics profitable or losing money?
As of the last Silexion Therapeutics earnings report, Silexion Therapeutics is currently losing money. Silexion Therapeutics's net profit (also called net income) for the twelve months ending Jun 30, 2026 was -$13.96 million, a 22.07% decrease year over year.
What was SLXN's earnings growth in the past year?
As of Silexion Therapeutics's earnings date in Aug 18, 2026, Silexion Therapeutics's earnings has grown year over year. SLXN earnings in the past year totalled -$13.96 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.